Upfront Surgery Versus NeoAdjuvant Chemotherapy Followed by Surgery for Resectable Advanced Gastric Cancer: SNAC Study

NCT06472063 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 684

Last updated 2024-06-24

No results posted yet for this study

Summary

Based on the concerns about the actual low strength of evidence of the efficacy of NAC on survival of proper gastric cancer treated with adequate D2 gastrectomy as compared to the results of optimal upfront surgery (S), and considering the actual difficulties of additional RCTs, the aim of this study is to assess the non-inferiority of upfront surgery alone with optimal D2 dissection compared to NAC regimens followed by surgery. Methods: This is a nationwide Multicenter observational retrospective study with matched comparison of two therapeutic strategies (NAC vs S). We will include patients with cT\>2, every cN M0, or with every T and N+ M0, histologically proven adenocarcinoma of the stomach, submitted either to pre- or peri-operative treatment and D2 gastrectomy or to upfront D2 gastrectomy, between January 2012 and December 2019, followed by adjuvant treatment when recommended.

All patients matching the inclusion/exclusion criteria will be registered into the study and classified into one of the two arms: a, patients who underwent pre- or perioperative treatment and D2 gastrectomy (NAC) or b, patients submitted to upfront D2 gastrectomy (S). Given the results reported in the "FLOT" trial, a 3-years OS of 55% in the control arm (NAC) was assumed. Three-year OS in the experimental arm (S) was assumed to be 47.4% under the null hypothesis of inferiority and 55% under the alternative hypothesis of non-inferiority. A sample size of 684 patients (342 in each arm) achieves 80% power to detect a non-inferiority margin Hazard Ratio of 1.25

Conditions

Interventions

OTHER

pre- or perioperative treatment and D2 gastrectomy

pre- or perioperative treatment and D2 gastrectomy

Sponsors & Collaborators

  • Azienda Ospedaliera Universitaria Senese

    collaborator OTHER
  • IRCCS Ospedale San Raffaele

    collaborator OTHER
  • Federico II University

    collaborator OTHER
  • Azienda Ospedaliero-Universitaria di Parma

    collaborator OTHER
  • Azienda Ospedaliero Universitaria Policlinico Modena

    collaborator OTHER
  • Istituti Tumori Giovanni Paolo II

    collaborator NETWORK
  • Fondazione IRCCS Policlinico San Matteo di Pavia

    collaborator OTHER
  • ASST Grande Ospedale Metropolitano Niguarda

    collaborator OTHER
  • Azienda Ospedaliera Sant'Anna

    collaborator OTHER
  • Ospedale di Circolo - Fondazione Macchi

    collaborator OTHER
  • Ospedale San Donato

    collaborator OTHER
  • Government hospital in Forlì, Italy

    collaborator OTHER
  • Istituti Ospitalieri di Cremona

    collaborator OTHER
  • Azienda Ospedaliero-Universitaria Careggi

    collaborator OTHER
  • Azienda ULSS di Verona e Provincia

    collaborator OTHER
  • Azienda Ospedaliera di Perugia

    collaborator OTHER
  • A.O. Ospedale Papa Giovanni XXIII

    collaborator OTHER
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

    collaborator OTHER
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    collaborator OTHER
  • Provincia Autonoma di Trento

    collaborator OTHER_GOV
  • University of Florence

    collaborator OTHER
  • Ospedale M. Bufalini Cesena

    collaborator OTHER
  • Azienda Ospedaliera di Padova

    collaborator OTHER
  • Ospedale Guglielmo da Saliceto, Piacenza

    collaborator UNKNOWN
  • Azienda Ospedaliera San Gerardo di Monza

    collaborator OTHER
  • A.O.U. Città della Salute e della Scienza

    collaborator OTHER
  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    collaborator OTHER
  • Ospedale Santo Stefano

    collaborator OTHER
  • Policlinico Abano Terme

    collaborator OTHER
  • Istituto Europeo di Oncologia

    collaborator OTHER
  • Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona

    collaborator OTHER
  • Humanitas Hospital, Italy

    collaborator OTHER
  • San Luigi Gonzaga Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-22
Primary Completion
2023-08-30
Completion
2024-09-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06472063 on ClinicalTrials.gov